Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden
Introduction Although there are many studies on the use of convalescent plasma (CP) for treatment of COVID-19, it is not clear (1) which groups of patients may benefit, (2) what dose of plasma to give, or (3) which antibody levels the plasma should contain. Previous phase I/II studies and literature...
Saved in:
| Main Authors: | Joakim Dillner, Johan Ursing |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e048337.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
by: Arsène Mekinian, et al.
Published: (2023-10-01) -
Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
by: Trishul Siddharthan, et al.
Published: (2021-01-01) -
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialResearch in context
by: Simone Hoffmann, et al.
Published: (2025-03-01) -
The effectiveness of convalescent plasma administered on the first day of admission for COVID-19 patients: an open-label randomized controlled trial
by: Saeed Mohammadi, et al.
Published: (2025-01-01) -
Unusual Cardiac Presentation of COVID-19 and Use of Convalescent Plasma
by: William R. Hartman, et al.
Published: (2020-01-01)